Hypogonadism and metabolic syndrome

Journal of Endocrinological Investigation

Volumn 34, Issue 7, 2011, Pages 557-567

  Corona, G ^a,b   Rastrelli, G ^a   Morelli, A ^a   Vignozzi, L ^a   Mannucci, E ^a   Maggi, M ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

^b Azienda USL di Bologna   (Italy)

Author keywords

Cardiovascular risk; Erectile dysfunction; Metabolic syndrome; Testosterone

Indexed keywords

SEX HORMONE; TESTOSTERONE;

ABDOMINAL OBESITY; ANDROGEN DEPRIVATION THERAPY; ANDROGEN THERAPY; CARDIOVASCULAR RISK; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; ERECTILE DYSFUNCTION; HORMONE BLOOD LEVEL; HUMAN; HYPOGONADISM; INSULIN SENSITIVITY; INTRAABDOMINAL FAT; LIPID STORAGE; METABOLIC SYNDROME X; NONHUMAN; ORGAN WEIGHT; PATHOGENESIS; PREVALENCE; REVIEW; RISK ASSESSMENT; SEMINAL VESICLE; SYSTEMATIC REVIEW; WAIST CIRCUMFERENCE;

ANIMALS; CARDIOVASCULAR DISEASES; CLINICAL TRIALS AS TOPIC; ERECTILE DYSFUNCTION; HUMANS; HYPOGONADISM; KAPLAN-MEIER ESTIMATE; MALE; MEDLINE; METABOLIC SYNDROME X; RISK FACTORS; TESTOSTERONE;

EID: 80054089894     PISSN: 03914097     EISSN: 17208386     Source Type: Journal    
DOI: 10.3275/7806     Document Type: Review

References (80)

1. Hajjar I, Kotchen TA. Trends in prevalence, awareness, treatment, and control of hypertension in the United States, 1988-2000. JAMA 2003, 290: 199-206. (Pubitemid 37430058)
2. Wägner AM, Wiebe JC, Boronat M, et al. Insulin resistance explains the relationship between novel cardiovascular risk factors and hypertension. The Telde Study. J Endocrinol Invest 2010, Oct 27 [Epub ahead of print]; doi: 10.3275/7325.
3. Corona G, Lee DM, Forti G, et al. EMAS Study Group. Age-related changes in general and sexual health in middle-aged and older men: results from the European Male Ageing Study (EMAS). J Sex Med 2010, 7: 1362-80.
4. Despres JP, Lemieux I. Abdominal obesity and metabolic syndrome. Nature 2006, 444: 881-7. (Pubitemid 46024995)
5. Corona G, Mannucci E, Forti G, Maggi M. Hypogonadism, ED, metabolic syndrome and obesity: a pathological link supporting cardiovascular diseases. Int J Androl 2009, 32: 587-98.
6. Corona G, Monami M, Boddi V, et al. Male sexuality and cardiovascular risk. A cohort study in patients with erectile dysfunction. J Sex Med 2010, 7: 1918-27.
7. Corona G, Monami M, Rastrelli G, et al. Testosterone and metabolic syndrome: a meta-analysis study. J Sex Med 2011, 8: 272-83.
8. Corona G, Monami M, Rastrelli G, et al. Is metabolic syndrome a useless category in subjects with high cardiovascular risk? Results from a cohort study in men with erectile dysfunction. J Sex Med 2011, 8: 504-11
9. Corona G, Rastrelli G, Vignozzi L, Mannucci E, Maggi M. Testosterone, cardiovascular disease and the metabolic sindrome. Best Pract Res Clin Endocrinol Metab 2010 in press.
10. Alberti KG, Eckel RH, Grundy SM, et al. International Diabetes Federation Task Force on Epidemiology and Prevention; Hational Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; International Association for the Study of Obesity. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 2009, 120: 1640-5.
11. Monami M, Bardini G, Lamanna C, et al. Liver enzymes and risk of diabetes and cardiovascular disease: results of the Firenze Bagno a Ripoli (FIBAR) study. Metabolism 2008, 57: 387-92. (Pubitemid 351178729)
12. Mannucci E, Monami M, Bardini G, et al. Metabolic syndrome and pulse pressure. Diabetes Obes Metab 2007, 9: 600-2. (Pubitemid 47018526)
13. Monami M, Marchionni N, Masotti G, Mannucci E. Prognostic value of International Diabetes Federation and Adult Treatment Panel III definitions of metabolic syndrome in Type 2 diabetic patients: what makes the difference? J Endocrinol Invest 2007, 30: 626-30. (Pubitemid 350104090)
14. Maggio M, Lauretani F, Ceda GP, et al. Association between hormones and metabolic syndrome in older Italian men. J Am Geriatr Soc 2006, 54: 1832-8. (Pubitemid 44915825)
15. Garni AS, Witt BJ, Howard DE, et al. Metabolic syndrome and risk of incident cardiovascular events and death: a systematic review and meta-analysis of longitudinal studies. J Am Coll Cardiol 2007, 49: 403-14. (Pubitemid 46135879)
16. Iturry-Yamamoto GR, Zago AC, Moriguchi EH, et al. Impact of metabolic syndrome and C-reactive protein on outcome after coronary stenting. J Endocrinol Invest 2009, 32: 383-6.
17. Guembe MJ, Toledo E, Barba J, et al. Association between metabolic syndrome or its components and asymptomatic cardiovascular disease in the RIVANA-study. Atherosclerosis 2010, Mar 9 [Epub ahead of print]; doi:10.1016/j.atherosclerosis.2010.03.004.
18. Scholze J, Alegria E, Ferri C, et al. Epidemiological and economic burden of metabolic syndrome and its consequences in patients with hypertension in Germany, Spain and Italy; a prevalence-based model. BMC Public Health 2010, 10: 529.
19. Rodrigues TC, Canani LH, Schvartzman P, Gross JL. Hypertension is the Metabolic Syndrome Component Most Strongly Associated with Microvascular Complications and Coronary Artery Calcification in Type 1 Diabetes. J Endocrinol Invest 2010, 34: e58-63.
20. Mancia G, De Backer G, Dominiczak A, et al.; The task force for the management of arterial hypertension of the European Society of Hypertension, The task force for the management of arterial hypertension of the European Society of Cardiology. Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 2007, 28: 1462-536.
21. Assmann G, Guerra R, Fox G, et al. Harmonizing the definition of the metabolic syndrome: comparison of the criteria of the Adult Treatment Panel III and the International Diabetes Federation in United States American and European populations. Am J Cardiol 2007, 99: 541-8. (Pubitemid 46215539)
22. Monami M, Marchionni N, Masotti G, Mannucci E. IDF and ATP-III definitions of metabolic syndrome in the prediction of all-cause mortality in type 2 diabetic patients. Diabetes Obes Metab 2007, 9: 350-3. (Pubitemid 46502054)
23. Monami M, Lambertucci L, Ungar A, et al. Is the third component of metabolic syndrome really predictive of outcomes in type 2 diabetic patients? Diabetes Care 2006, 29: 2515-7. (Pubitemid 44912264)
24. Boddi V, Corona G, Monami M, et al. Priapus is happier with Venus than with Bacchus. J Sex Med 2010, Jul 7 [Epub ahead of print]; doi: 10.1111/J.1743-6109.2010.01887.x.
25. Corona G, Monami M, Boddi V, et al. Low testosterone is associated with an increased risk of MACE lethality in subjects with erectile dysfunction. J Sex Med 2010, 7: 1557-64.
26. Corona G, Mannucci E, Petrone L et al. A comparison of NCEP-AT-PIII and IDF metabolic syndrome definitions with relation to metabolic syndrome-associated sexual dysfunction. J Sex Med 2007, 4: 789-96. (Pubitemid 46779316)
27. Corona G, Mannucci E, Fisher AD, et al. Cardiovascular risk engines can help in selecting patients to be evaluated by dynamic penile color doppler ultrasound. J Endocrinol Invest 2008, 31: 1058-62.
28. Montorsi P, Ravagnani PM, Galli S, et al. Association between erectile dysfunction and coronary artery disease: Matching the right target with the right test in the right patient. Eur Urol 2006, 50: 721-31. (Pubitemid 44332685)
29. Thompson IM, Tangen CM, Goodman PJ, Probstfield JL, Moinpour CM, Coltman CA. Erectile dysfunction and subsequent cardiovascular disease. JAMA 2005, 294: 2996-3002. (Pubitemid 41817661)
30. Corona G, Fagioli G, Mannucci E, et al. Penile doppler ultrasound in patients with ED: role of peak systolic velocity measured in the flaccid state in predicting arteriogenic ED and silent coronary artery disease. J Sex Med 2008, 5: 2623-34.
31. Corona G, Forti G, Maggi M. Why can patients with erectile dysfunction be considered lucky? The association with testosterone deficiency and metabolic syndrome. Aging Male 2008, 11: 193-9.
32. Brand JS, van der Tweel I, Grobbee DE, Emmelot-Vonk MH, van der Schouw YT. Testosterone, sex hormone-binding globulin and the metabolic syndrome: a systematic review and meta-analysis of observational studies. Int J Epidemiol 2010, Sep 24 [Epub ahead of print]; doi: 10.1093/ije/dyq158.
33. Corona G, Rastrelli G, Forti G, Maggi M. Update in Testosterone Therapy for Men. J Sex Med 2011 in press; doi: 10.1111/j.1743-6109.2010.02200.x.
34. Lenzi A, Balercia G, Bellastella A, et al. Epidemiology, diagnosis, and treatment of male hypogonadotropic hypogonadism. J Endocrinol Invest 2009, 32: 934-8.
35. Morelli A, Corona G, Filippi S, et al. Which patients with sexual dysfunction are suitable for testosterone replacement therapy? J Endocrinol Invest 2007, 30: 880-8. (Pubitemid 351166313)
36. Petak SM, Nankin HR, Spark RF, Swerdloff RS, Rodriguez-Rigau LJ; American Association of Clinical Endocrinologists. American Association of Clinical Endocrinologists Medical Guidelines for clinical practice for the evaluation and treatment of hypogonadism in adult male patients-2002 update. Endocr Pract 2002, 8: 440-56.
37. Bhasin S, Cunningham GR, Hayes FJ, et al. Task Force, Endocrine Society. Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2010, 95: 2536-59.
38. Wang C, Nieschlag E, Swerdloff R, et al. International Society of Andrology; International Society for the Study of Aging Male; European Association of Urology; European Academy of Andrology; American Society of Andrology. Investigation, treatment, and monitoring of late-onset hypogonadism in males: ISA, ISSAM, EAU, EAA, and ASA recommendations. Eur Urol 2009, 55: 121-30.
39. Corona G, Rastrelli G, Balercia G, et al. Perceived reduced sleep-related erections in subjects with erectile dysfunction: psycho-biological correlates. J Sex Med 2011, 8: 1780-8.
40. Zumoff B, Strain GW, Miller LK, et al. Plasma free and non-sex-hormone-binding-globulin-bound testosterone are decreased in obese men in proportion to their degree of obesity. J Clin Endocrinol and Metab 1990, 71: 929-31.
41. Corona G, Mannucci E, Fisher AD, et al. Low levels of androgens in men with erectile dysfunction and obesity. J Sex Med 2008, 5: 2454-63.
42. Corona G, Mannucci E, Petrone L, et al. Association of hypogonadism and type Il diabetes in men attending an outpatient erectile dysfunction clinic. Int J Impot Res 2006, 18: 190-7. (Pubitemid 43336487)
43. Wu FC, Tajar A, Beynon JM, et al. EMAS Group. Identification of late-onset hypogonadism in middle-aged and elderly men. N Engl J Med 2010, 363: 123-35.
44. Gatti A, Mandosi E, Fallarino M, et al. Metabolic syndrome and erectile dysfunction among obese non-diabetic subjects. J Endocrinol Invest 2009, 32: 542-5.
45. Corona G, Boddi V, Balercia G, et al. The effect of statin therapy on testosterone levels in subjects consulting for erectile dysfunction. J Sex Med 2010, 7:1547-56.
46. Kanat M, Serin E, Tunckale A, et al. A multi-center, open label, crossover designed prospective study evaluating the effects of lipid lowering treatment on steroid synthesis in patients with Type 2 diabetes (MODEST Study). J Endocrinol Invest 2009, 32: 852-6.
47. Corona G, Mannucci E, Schulman C, et al. Psychobiologic correlates of the metabolic syndrome and associated sexual dysfunction. Eur Urol 2006, 50: 595-604. (Pubitemid 44189051)
48. Corona G, Mannucci E, Petrone L, et al. NCEP-ATP-III defined metabolic syndrome, type 2 diabetes mellitus and prevalence of hypogonadism in male patients with sexual dysfunction. J Sex Med 2007, 4: 1038-45. (Pubitemid 47079637)
49. Aversa A, Bruzziches R, Francomano D, Spera G, Lenzi A. Efficacy and safety of two different testosterone undecanoate formulations in hypogonadal men with metabolic syndrome. J Endocrinol Invest 2010, 33: 776-83.
50. Singh R, Artaza JN, Taylor WE, et al. Testosterone inhibits adipogenic differentiation in 3T3-L1 cells: nuclear translocation of androgen receptor complex with beta-catenin and T-cell factor 4 may bypass canonical Wnt signaling to down-regulate adipogenic transcription factors. Endocrinology 2006, 147: 141-54.
51. Gupta V, Bhasin S, Guo W, et al. Effects of dihydrotestosterone on differentiation and proliferation of human mesenchymal stem cells and preadipocytes. Mol Cell Endocrinol 2008, 296: 32-40.
52. Mårin P, Odén B, Björntorp P. Assimilation and mobilization of triglycerides in subcutaneous abdominal and femoral adipose tissue in vivo in men: effects of androgens. J Clin Endocrinol Metab 1996, 80: 239-43.
53. Allan CA, Forbes EA, Strauss BJ, McLachlan Rl. Testosterone therapy increases sexual desire in ageing men with low-normal testosterone levels and symptoms of androgen deficiency. Int J Impot Res 2008, 20: 396-401.
54. Lin HY, Xu Q, Yeh S, Wang RS, Sparks JD, Chang C. Insulin and leptin resistance with hyperleptinemia in mice lacking androgen receptor. Diabetes 2005, 54: 1717-25. (Pubitemid 40770762)
55. Lin HY, Yu IC, Wang RS, et al. Increased hepatic steatosis and insulin resistance in mice lacking hepatic androgen receptor. Hepatology 2008, 47: 1924-35.
56. Yu IC, Lin HY, Liu NC, et al. Hyperleptinemia without obesity in male mice lacking androgen receptor in adipose tissue. Endocrinology 2008, 149: 2361-8.
57. Burcelin R, Thorens B, Glauser M, Gaillard RC, Pralong FP. Gonadotropin-releasing hormone secretion from hypothalamic neurons: stimulation by insulin and potentiation by leptin. Endocrinology 2003, 144: 4484-91. (Pubitemid 37204848)
58. Zhang XH, Filippi S, Morelli A, et al. Testosterone restores diabetes-induced erectile dysfunction and sildenafil responsiveness in two distinct animal models of chemical diabetes. J Sex Med 2006, 3: 253-64.
59. Vignozzi L, Morelli A, Filippi S, et al. Testosterone regulates RhoA/Rho-kinase signaling in two distinct animal models of chemical diabetes. J Sex Med 2007, 4: 620-30.
60. Dhindsa S, Prabhakar S, Sethi M, Bandyopadhyay A, Chaudhuri A, Dandona P. Frequent occurrence of hypergonadotropic hypogonadism in type 2 diabetes. J Clin Endocrinol Metab 2004, 89: 5462-8. (Pubitemid 39518427)
61. Brüning JC, Gautam D, Burks DJ, et al. Role of brain insulin receptor in control of body weight and reproduction. Science 2007, 289: 2122-5.
62. Giagulli VA, Kaufman JM, Vermeulen A. Pathogenesis of the decreased androgen levels in obese men. J Clin Endocrinol Metab 1994, 79: 997-1000. (Pubitemid 24342237)
63. Vermeulen A, Kaufman JM, Deslypere JP, Thomas G. Attenuated luteinizing hormone (LH) pulse amplitude but normal LH pulse frequency, and its relation to plasma androgens in hypogonadism of obese men. J Clin Endocrinol Metab 1993, 76: 1140-6. (Pubitemid 23155426)
64. Loves S, Ruinemans-Koerts J, de Boer H. Letrozole once a week normalizes serum testosterone in obesity-related male hypogonadism. Eur J Endocrinol 2008, 158: 741-7. (Pubitemid 351639613)
65. Pitteloud N, Hardin M, Dwyer AA, et al. Increasing insulin resistance is associated with a decrease in Leydig cell testosterone secretion in men. J Clin Endocrinol Metab 2005, 90: 2636-41. (Pubitemid 40686302)
66. Pitteloud N, Dwyer AA, Decruz S, et al. Inhibition of luteinizing hormone secretion by testosterone in men requires aromatization for its pituitary but not its hypothalamic effects: evidence from the tandem study of normal and gonadotropin-releasing hormone-deficient men. J Clin Endocrinol Metab 2008, 93: 784-91. (Pubitemid 351398554)
67. Pasquali R, Casimirri F, De lasio R, et al. Insulin regulates testosterone and sex hormone-binding globulin concentrations in adult normal weight and obese men. J Clin Endocrinol Metab 1995, 80: 654-8.
68. Isidori AM, Caprio M, Strollo F, et al. Leptin and androgens in male obesity: evidence for leptin contribution to reduced androgen levels. J Clin Endocrinol Metab 1999, 84: 3673-80. (Pubitemid 30645224)
69. Isidori AM, Strollo F, Morè M, et al. Leptin and aging: correlation with endocrine changes in male and female healthy adult populations of different body weights. J Clin Endocrinol Metab 2000, 85: 1954-62. (Pubitemid 32269305)
70. Morelli A, Marini M, Mancina R, et al. Sex steroids and leptin regulate the "first Kiss" (KiSS 1/G-protein-coupled receptor 54 system) in human gonadotropin-releasing-hormone-secreting neuroblasts. J Sex Med 2008, 5: 1097-113. (Pubitemid 351606699)
71. Kelesidis T, Kelesidis I, Chou S, Mantzoros CS. Narrative review: the role of leptin in human physiology: emerging clinical applications. Ann Intern Med 2010, 152: 93-100.
72. Heymsfield SB, Greenberg AS, Fujioka K, et al. Recombinant leptin for weight loss in obese and lean adults: a randomized, controlled, dose-escalation trial. JAMA 1999, 282: 1568-75. (Pubitemid 29504050)
73. Morales V, Santana P, Díaz R, et al. Intratesticular delivery of tumor necrosis factor-alpha and ceramide directly abrogates steroidogenic acute regulatory protein expression and Leydig cell steroidogenesis in adult rats. Endocrinology 2003, 144: 4763-72. (Pubitemid 37378390)
74. MacEwan DJ. Interactions between TNF and GnRH. Neurochem Res 2008, 33: 678-82.
75. Panchal SK, Brown L. Rodent models for metabolic syndrome research. J Biomed Biotechnol 2011, 2011: 351982.
76. West DB, Boozer CN, Moody DL, Atkinson RL. Dietary obesity in nine inbred mouse strains. Am J Physiol 1992, 262: R1025-32.
77. Vignozzi L, Morelli A, Filippi S, et al. Farnesoid X receptor activation improves erectile function in animal models of metabolic syndrome and diabetes. J Sex Med 2011, 8: 57-77.
78. Filippi S, Vignozzi L, Morelli A, et al. Testosterone partially ameliorates metabolic profile and erectile responsiveness to PDE5 inhibitors in an animal model of male metabolic syndrome. J Sex Med 2009, 6: 3274-88.
79. Lu Y, Jiang B, Xia F, et al. Changes of pituitary and penile structure in male adult rats following castration and high-fat diet. J Endocrinol Invest 2011, 34: 111-6.
80. Morelli A, Vignozzi L, Maggi M, Adorini L. Farnesoid X receptor activation improves erectile dysfunction in models of metabolic syndrome and diabetes. Biochim Biophys Acta 2010, Nov 5 [Epub ahead of print]; doi: 10.1016/j.bbadis.2010.10.013.